StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$40.59+2.14 (+5.57%)

Close on Nov 18, 2026Market cap $41.28MP/E –Yield –

IRulya Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for IRulya Therapeutics

IRulya Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More IRulya Therapeutics figures

See a number that looks wrong?